The Greater Cannabis Company, Inc. (GCAN)

0.0008 +0.0001 (+14.29%) As of 10:53AM EDT. Market open.

The Greater Cannabis Company, Inc.

2833 Smith Avenue
Suite 333
Baltimore, MD 21209
United States
443 738 4051
https://www.gcanrx.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 1

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Aitan Zacharin	Chairman, President, CEO, Acting CFO & Treasurer	120k	N/A	1983
Motti Stenge	Chief Operating Officer	N/A	N/A	N/A
Dr. Adi Aran M.D.	Chief Scientific Advisor	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson's disease, Alzheimer's disease, and other neuropsychiatric disorders. The Greater Cannabis Company, Inc. was founded in 2014 and is based in Baltimore, Maryland.

Corporate governance

The Greater Cannabis Company, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.